trial

Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults

NCTId NCT02261519
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Terminated
Enrollment 280 (actual)
Sponsored by SyneuRx International (Taiwan) Corp
Primary completion 2023-11-29
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Terminated
Enrollment
280 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2017-03-29
Primary completion
2023-11-29
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
NaBen®

Sponsors

SyneuRx International (Taiwan) CorpLead Sponsor

Sites

1 total
Pasadena, United States

Linked catalysts

1
Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophre — primary completion2023-11-29

Facts & assertions

4 sourced
Enrollment
280
Phase
PHASE2,PHASE3
Primary Completion Date
2023-11-29
Status
TERMINATED
relationships
The graph out of here
drug
NaBen®
drug
lead_sponsor
SyneuRx International (Taiwan) Corp
company
indication
Schizophrenia
indication
Schizophrenia
indication